Enrique Alvarez, MD, PhD
Affiliations: | Neurology | University of Colorado, Boulder, Boulder, CO, United States |
Area:
multiple sclerosis, biomarkersGoogle:
"Enrique Alvarez"Mean distance: 20.48 (cluster 46)
Parents
Sign in to add mentor| Anne Haney Cross | post-doc | 2010-2013 | Washington University School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Longbrake EE, Hua LH, Mowry EM, et al. (2022) The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders. 68: 104143 |
| Ziemssen T, Arnold DL, Alvarez E, et al. (2022) Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology. 13: 852563 |
| Alvarez E, Nair KV, Hoyt BD, et al. (2021) Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Multiple Sclerosis and Related Disorders. 55: 103170 |
| Vollmer TL, Cohen JA, Alvarez E, et al. (2020) Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 46: 102454 |
| Vollmer BL, Nair K, Sillau S, et al. (2020) Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology |
| Vollmer BL, Wallach AI, Corboy JR, et al. (2020) Serious safety events in rituximab-treated multiple sclerosis and related disorders. Annals of Clinical and Translational Neurology |
| Almuklass AM, Capobianco RA, Feeney DF, et al. (2019) Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders. 38: 101508 |
| Vollmer B, Ontaneda D, Harris H, et al. (2019) Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences. 407: 116498 |
| Wolf AB, Ryerson LZ, Pandey K, et al. (2019) Rituximab-induced serum sickness in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 36: 101402 |
| Lovett-Racke AE, Gormley M, Liu Y, et al. (2019) B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. Journal of Neuroimmunology. 332: 187-197 |